Konstanz, Germany – PRIME Proteins, a cutting-edge leader in AI-driven protein design (https://www.primeproteins.ai/), is thrilled to announce a long-term partnership with Trenzyme GmbH (https://trenzyme.com/), a renowned contract research organization specializing in recombinant protein production and characterization. This collaboration marks a significant milestone in the fusion of artificial intelligence and biotechnology, aiming to revolutionize the development of novel protein variants for a wide range of applications.
Under this partnership, PRIME Proteins will leverage its advanced AI-powered toolset to design innovative protein variants with optimized properties such as stability, activity, and solubility. These AI-generated designs will then be handed over to Trenzyme, whose expert team will express and characterize the proteins, focusing on their soluble expression profiles. By combining PRIME Proteins’ computational prowess with Trenzyme’s extensive expertise in protein production, the collaboration promises to accelerate the discovery and refinement of high-performance proteins tailored to meet the needs of the pharmaceutical, biotech, and research sectors.
“We are excited to join forces with Trenzyme, a company that shares our commitment to pushing the boundaries of scientific innovation,” said Marcel Stadler, CEO at PRIME Proteins. “Our AI technology allows us to explore vast protein design spaces with unprecedented speed and precision. Partnering with Trenzyme’s world-class capabilities in protein expression and characterization ensures that these designs are brought to life efficiently and effectively, delivering real-world solutions to our clients.”
Trenzyme, with over two decades of experience in custom protein production, brings a robust infrastructure and a highly skilled team to the table. Their expertise in handling complex protein variants across multiple expression systems, including E. coli, yeast, insect, and mammalian cells perfectly complements PRIME Proteins’ design capabilities. Together, the two companies aim to streamline the process from in silico protein design to tangible, functional proteins ready for downstream applications.
The collaboration is already underway, with initial projects focusing on designing protein variants for therapeutic and industrial purposes. Both companies are committed to a transparent and iterative approach, where data from Trenzyme’s characterization efforts will feed back into PRIME Proteins’ AI models, enhancing their predictive accuracy and generating even more effective designs over time.
This partnership underscores PRIME Proteins’ mission to harness AI for protein engineering and Trenzyme’s dedication to delivering tailored biotechnological solutions. As the demand for novel proteins grows across industries, this alliance positions both companies at the forefront of innovation, ready to meet the challenges of tomorrow.
For more information about PRIME Proteins and its AI-powered protein design platform, visit https://www.primeproteins.ai/. To learn more about Trenzyme’s protein production and characterization services, visit https://trenzyme.com/.
